Seattle Genetics Announces Trial Data for Adcetris, CHOP against ALCL


Seattle Genetics has announced preliminary data from one arm of a three-arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of Adcetris (brentuximab vedotin) with CHOP or CH-P combination chemotherapy in patients with newly diagnosed, CD30-positive mature T- and NK-cell lymphomas.

The data was reported at the European Society for Medical Oncology meeting in Vienna, Austria.

The arm of the study from which data was presented featured Adcetris administered in sequence with CHOP chemotherapy in newly diagnosed patients with systemic anaplastic large cell lymphoma, a subtype of mature T-cell lymphomas.

"The preliminary data from the sequential treatment arm of this phase I study show that side effects were manageable and there are also some encouraging data on activity," according to Michelle Fanale, M.D., of MD Anderson Cancer Center. "We look forward to reporting additional data from the combination arms of the study at an upcoming medical congress."

Data from the other arms are expected later this year.

Source: Seattle Genetics

LymphomaInfo Social